🌟 This week’s #OncFive 5⃣: 🚀 Priority review for periop EV + pembro in MIBC 💉 @fda.gov review extended for SC isatuximab in myeloma 📉 Pembro combos miss mark in frontline ccRCC 🧪 Daraxonrasib shows promise in PDAC 🌍 EC clears tovorafenib for pLGG Learn more 🔗: www.onclive.com/view/the-onc...

🧬 Neoadjuvant pembrolizumab achieved high pCR rates with no relapses at 3 years in high-risk dMMR/MSI-H colorectal cancer—raising the possibility of organ preservation and chemo-free strategies. Read more ➡️ www.onclive.com/view/neoadju... #ColorectalCancer #GIonc #Immunotherapy #MSIhigh

🧬 Adding fecal microbiota transplantation (FMT) to ICI therapy significantly improved median PFS in metastatic RCC, with signals for better responses and survival in the TACITO trial 📊 Read more ➡️ www.onclive.com/view/fecal-m... #KidneyCancer #RCC #Oncology

Researchers at Roswell Park Comprehensive Cancer Center developed a two‑step therapeutic strategy designed to selectively eliminate tumors driven by TP53 mutations. @roswellpark.bsky.social @theaacr.bsky.social #AACR26 #oncology www.onclive.com/view/aacr-20...

WATCH: Jesús Berdeja, MD, outlines key considerations for the long-term care of patients with relapsed/refractory multiple myeloma who receive CAR T-cell therapy. #mmsm #hematology #oncology See our site for more myeloma insights! www.onclive.com/clinical/mul...

WATCH: Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, note data from a study of PD-L1 expression as a marker of response to TKIs in EGFR-mutated NSCLC. @weillcornell.bsky.social #lcsm #oncology www.onclive.com/view/drs-lee...

WATCH: Timothy Shaw, PhD, explains how establishing community in the workplace can help oncology professionals achieve work-life harmony. @moffittnews.bsky.social #oncology Read on for further insights about how to reduce burnout in oncology: www.onclive.com/view/confere...

WATCH: Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the role for PD-L1 expression as a biomarker for treatment response in EGFR-mutant NSCLC. @weillcornell.bsky.social #lcsm #oncology www.onclive.com/view/drs-lee...

WATCH: Rena D. Callahan, MD, discusses the implications of the NATALEE trial of adjuvant ribociclib plus endocrine therapy in HR-positive early breast cancer. @uclahealth.org @dgsomucla.bsky.social #bcsm #oncology www.onclive.com/view/dr-call...

🧬 Taletrectinib continues to demonstrate robust and durable efficacy in TKI-naive ROS1+ NSCLC, with ~90% ORR, rapid responses, and encouraging PFS in updated TRUST-I and TRUST-II data. 📊 Read more ➡️ www.onclive.com/view/taletre... #LungCancer #NSCLC #ROS1 # #Oncology

🧬 RAS(ON) inhibition moves into the frontline PDAC setting. Early data show daraxonrasib demonstrates antitumor activity with or without chemotherapy in metastatic pancreatic cancer. 📊 Read more ➡️ www.onclive.com/view/daraxon... #PancreaticCancer #GIonc #KRAS #Oncology

Australia’s TGA has approved tafasitamab in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed/refractory follicular lymphoma #lymsm #oncology Read more on the latest global health authority to green light this combination: www.onclive.com/view/tafasit...

🧬 Cracking resistance in EGFR-mutated NSCLC. Preclinical data show ABK-EGFR-1 demonstrates antitumor activity in EGFR C797S–driven xenograft models—a key resistance mutation emerging after osimertinib and other EGFR TKIs. 📊 Read more ➡️ www.onclive.com/view/abk-egf... #LungCancer #NSCLC #EGFR #AACR26

The FDA has extended the review period for a BLA seeking the approval of subcutaneous isatuximab delivered via an on-body injector for patients with multiple myeloma #mmsm #oncology Read more: www.onclive.com/view/fda-ext...

🧬 Neoadjuvant chemotherapy shows lasting impact in high-risk UTUC. Long-term data demonstrate meaningful survival benefits with neoadjuvant chemotherapy prior to surgery. 📊 Read more ➡️ www.onclive.com/view/neoadju... #BladderCancer #GUonc #oncology

💥 Recurrence was associated with post-treatment ctDNA-positivity in locally advanced HNSCC according to data from a phase 2 trial, providing crucial information to trial investigators. Read more here ➡️: www.onclive.com/view/post-tr... #hncsm #oncology #AACR26 @theaacr.bsky.social

🧬 Long-term follow-up confirms a sustained OS benefit with tebentafusp in HLA-A*02:01–positive metastatic uveal melanoma, with improvements maintained out to 3–5 years vs investigator’s choice therapy. 📊 Read more ➡️ www.onclive.com/view/tebenta... #Melanoma #UvealMelanoma #Oncology #AACR26

Pembrolizumab plus lenvatinib/belzutifan, as well as a coformulation of pembrolizumab/quavonlimab in combination with lenvatinib, failed to yield PFS or OS benefits in frontline advanced clear cell RCC #kcsm #oncology An update from the phase 3 LITESPARK-012 trial: www.onclive.com/view/pembrol...

🌏 Belantamab mafodotin + bortezomib/dexamethasone (BVd) has been approved in China for R/R multiple myeloma, backed by phase 3 DREAMM-7 data showing significant PFS and OS improvements vs DVd. 📊 Read more ➡️ www.onclive.com/view/belanta... #MultipleMyeloma #HemeOnc #ClinicalTrials #Oncology

WATCH: Marija Balic, MD, PhD, discusses the potential role of tumor-informed ctDNA testing in early triple-negative breast cancer. @upmchillmancc.bsky.social @theaacr.bsky.social #bcsm #oncology See our coverage of the #AACR26 for more insights! www.onclive.com/conference/a...

Cilta-cel demonstrated feasibility in the treatment of patients with high-risk smoldering multiple myeloma in the phase 2 CAR-PRISM trial. @danafarber.bsky.social @theaacr.bsky.social #AACR26 #mmsm #hematology www.onclive.com/view/cilta-c...

Molecular testing identified actionable alterations in high proportions of patients with breast and colorectal cancers, regardless of ctDNA status. @theaacr.bsky.social #AACR26 #bcsm #crcsm #oncology www.onclive.com/view/oncoext...

Douglas B. Johnson, MD, MSCI, of @vumedicine.bsky.social discusses the use of TIL therapy in melanoma, including patient selection, sequencing, timing, and emerging applications beyond skin cancer. #oncology #melanoma www.onclive.com/view/selecti...

🧬 Early-phase data show zoldonrasib delivers promising efficacy and a favorable safety profile in heavily pretreated KRAS G12D–mutated NSCLC—a space with no approved targeted options. 📊 Read more ➡️ www.onclive.com/view/zoldonr... #LungCancer #NSCLC #KRAS #TargetedTherapy #Oncology #AACR26

WATCH: Fangdi Sun, MD, discusses how biomarker testing can help navigate the complexity of treatment decision-making across the spectrum of head and neck cancers. @stanfordmedicine.bsky.social #hncsm #oncology www.onclive.com/view/dr-sun-...

After approving perioperative enfortumab vedotin plus pembrolizumab in November 2025 for cisplatin-ineligible MIBC, the FDA has granted priority review for the combination in the cisplatin-eligible population. #blcsm #oncology Read more: www.onclive.com/view/periope...

Relapse following allo-HSCT remains frequent and represents an ongoing therapeutic challenge for patients with myelofibrosis or BP-MPNs. @theebmt.bsky.social #EBMT26 #hematology #oncology www.onclive.com/view/retrosp...

With the @theaacr.bsky.social Annual Meeting officially underway, experts preview some of the most anticipated abstracts, including key data in lung, breast, and ovarian cancers #AACR26 #oncology Sign up and read our exclusive preview and expert insights: www.onclive.com/view/oncolog...

WATCH: Alicia Morgans, MD, MPH, of @danafarber.bsky.social discusses the safety profile and AE management of mevrometostat in mCRPC. #oncology #pcsm #CRPC www.onclive.com/view/dr-morg...

WATCH: Taigo Kato, MD, PhD, discusses the background of the MONSTAR-SCREEN-3 in resectable RCC and the key findings from the study. #oncology #GU26 #RCC #kcsm www.onclive.com/view/dr-kato...

WATCH: Michael Schweizer, MD, of @fredhutch.org discusses the mechanism of action of mevrometostat and early-phase data with the agent in mCRPC. #oncology #pcsm #prostatecancer www.onclive.com/view/dr-schw...

Meghan R. Flanagan, MD, MPH, discusses the evolution of radiation therapy protocols following surgery for patients with breast cancer. @fredhutch.org @uwmedicine.bsky.social #MBCC26 #bcsm #oncology www.onclive.com/view/dr-flan...

Sara Nunnery, MD, MSCI, of Tennessee Oncology stopped by to record the next episode of Breast Cancer Briefing to unpack the latest news in breast cancer research! Stay tuned to onclive.com for all of the highlights from our interview #oncology #LightsCameraMJH #bcsm

Thank you to our first interviewee of the day @mpishvaian.bsky.social of Johns Hopkins who discussed biomarkers in GI cancers. Check back on onclive.com for all of the highlights from our conversation #oncology #LightsCameraMJH #GIcancer

We are all set and excited for our studio day recordings! Stay tuned to onclive.com for highlights from our sessions featuring conversations with top oncologists from across the country. #oncology #LightsCameraMJH

WATCH: Ranee Mehra, MD, highlights the importance of PD-L1 testing for head and neck cancer. #hncsm #oncology Check out our head and neck cancer page for more expert insights! www.onclive.com/clinical/hea...

WATCH: Meghan R. Flanagan, MD, MPH, discusses the multidisciplinary complexities that arise when trying to coordinate de-escalated breast cancer care. @fredhutch.org @uwmedicine.bsky.social #MBCC26 #bcsm #oncology www.onclive.com/view/dr-flan...

WATCH: Rena D. Callahan, MD, spotlights the future of triple-negative breast cancer management. @uclahealth.org #bcsm #oncology Check out our breast cancer page for more expert insights! www.onclive.com/clinical/bre...

Meghan R. Flanagan, MD, MPH, notes takeaways from a multidisciplinary tumor board discussion on how genomic assays can guide treatment decisions for DCIS. @fredhutch.org @uwmedicine.bsky.social #MBCC26 #bcsm #oncology www.onclive.com/view/dr-flan...

🧬 From osimertinib monotherapy to osimertinib + chemo and emerging regimens like amivantamab + lazertinib, clinicians now face key trade-offs in efficacy, toxicity, and sequencing. Read more ➡️ www.onclive.com/view/unpacki... #LungCancer #NSCLC #PrecisionOncology #TargetedTherapy #Oncology

Aaron Gerds, MD, MS, of Cleveland Clinic, breaks down the rationale for targeting CALR mutations and the drive for precision medicine approaches in MPNs #oncology Watch more from the interview here: www.onclive.com/view/dr-gerd...

🚀 The FDA has granted Fast Track designation to OPN-6602, an oral EP300/CBP inhibitor targeting novel transcriptional dependencies in heavily pretreated R/R multiple myeloma. 🧬 Read more ➡️ www.onclive.com/view/fda-gra... #MultipleMyeloma #HemeOnc #ClinicalTrials #Oncology

Christian Capitini has been named the next director of the University of Wisconsin Carbone Cancer Center. #oncology www.onclive.com/view/christi...

The NCCN has updated its 2026 Clinical Practice Guidelines for breast cancer screening and diagnosis to include Clairity Breast, an AI-based tool that analyzes mammograms and assesses future risk for breast cancer development #bcsm #oncology Read more: www.onclive.com/view/clairit...

WATCH: Bradley J. Monk, MD, FACS, FACOG, of Florida Cancer Specialists & Research Institute discusses the final analysis of the phase 3 KEYNOTE-B96 trial in platinum-resistant recurrent ovarian cancer. #Oncology #SGO2026 #gynsm www.onclive.com/view/dr-monk...

🧬 Mirvetuximab soravtansine + carboplatin demonstrated encouraging antitumor activity in platinum-sensitive ovarian cancer, supporting expansion of this ADC beyond the platinum-resistant setting. 📊 Read more ➡️ www.onclive.com/view/mirvetu... #gyncsm #oncology #SGOAM26

💊 Promising data from #SGOAM26: Tisotumab vedotin + carboplatin + pembrolizumab ± bevacizumab delivered a 65.8% response rate and a median OS of 28 months in first-line recurrent/metastatic cervical cancer. Learn more: 🔗 www.onclive.com/view/tisotum... #gyncsm #medtwitter #oncology

🎙️Watch or listen to the latest episode of Breast Cancer Briefing with Sara Nunnery, MD, & @neil-iyengarmd.bsky.social! @winshipcancer.emory.edu #bcsm #oncology www.onclive.com/view/lifesty...

WATCH: Alexander Olawaiye, MD, of @upmchillmancc.bsky.social discusses the final overall survival data from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer. #ovca #gynsm #SGOAM26 www.onclive.com/view/dr-olaw...

Manish Patel, DO, discusses future directions for investigating hormonal plus immune therapies for the treatment of patients with salivary gland cancer. #hncsm #oncology www.onclive.com/view/dr-pate...